Home > Documents in Process > Safety and evidence of CO2 as a vascular contrast agent as an alternative to iodine-based contrast media in vascular procedures: a systematic review by the ESUR Contrast Medium Safety Committee. > print

001     282472
005     20251121165706.0
024 7 _ |a 10.1007/s00330-025-12001-5
|2 doi
024 7 _ |a pmid:40968298
|2 pmid
024 7 _ |a 0938-7994
|2 ISSN
024 7 _ |a 1432-1084
|2 ISSN
024 7 _ |a 1613-3749
|2 ISSN
024 7 _ |a 1613-3757
|2 ISSN
024 7 _ |a (ISSN
|2 ISSN
024 7 _ |a DES
|2 ISSN
024 7 _ |a SUPPLEMENTS)
|2 ISSN
037 _ _ |a DZNE-2025-01295
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Wawer Matos Reimer, Robert P
|b 0
245 _ _ |a Safety and evidence of CO2 as a vascular contrast agent as an alternative to iodine-based contrast media in vascular procedures: a systematic review by the ESUR Contrast Medium Safety Committee.
260 _ _ |a Heidelberg
|c 2025
|b Springer
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1763740579_6324
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a This systematic review aims to analyse the different safety aspects and evidence of CO2 as a contrast agent in vascular applications as an alternative to iodine-based contrast media (ICM). The review addresses clinical applications, contraindications, safety measures, and the impact of CO2 on the risk reduction of contrast-associated acute kidney injury (CA-AKI).A systematic literature search was conducted across PubMed, Web of Science, Embase, and Cochrane Library, focusing on relevant literature centred around clinical questions by the Contrast Media Safety Committee of the European Society of Urogenital Radiology.Eleven studies encompassing meta-analyses, randomised controlled trials, and comparative studies were included. The review found that CO2 angiography is a safe alternative to ICM in various vascular applications, especially in patients at risk for CA-AKI. CO2 is associated with a higher incidence of minor, non-serious adverse events compared to ICM. No critical dose for CO2 is established, but safe administration protocols and measures were outlined. CO2 demonstrated a lower incidence of CA-AKI in peripheral arterial disease (PAD) procedures, but evidence in endovascular aneurysm repair (EVAR) was less conclusive.CO2 is a safe alternative to ICM in vascular procedures, potentially reducing the risk of CA-AKI, especially in PAD procedures. However, more large-scale RCTs are needed to confirm these findings and further investigate other risk factors contributing to CA-AKI in both EVAR and PAD procedures.Question What safety aspects and evidence support CO2 use as a contrast agent in vascular applications instead of ICM? Findings CO2 angiography is safe when considering specific safety measures and clinical applications; evidence on the reduction of ICM volume and CA-AKI is limited. Clinical relevance CO2 angiography offers an alternative to ICM, especially in CA-AKI risk patients. More large-scale, multicentre RCTs are required to strengthen the evidence and to investigate other risk factors due to a high residual risk of CA-AKI when using CO2 angiography.
536 _ _ |a 353 - Clinical and Health Care Research (POF4-353)
|0 G:(DE-HGF)POF4-353
|c POF4-353
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
650 _ 7 |a Acute kidney injury
|2 Other
650 _ 7 |a Angiography
|2 Other
650 _ 7 |a Carbon dioxide
|2 Other
650 _ 7 |a Contrast media
|2 Other
650 _ 7 |a Safety
|2 Other
650 _ 7 |a Contrast Media
|2 NLM Chemicals
650 _ 7 |a Carbon Dioxide
|0 142M471B3J
|2 NLM Chemicals
650 _ 7 |a Iodine
|0 9679TC07X4
|2 NLM Chemicals
650 _ 2 |a Contrast Media: adverse effects
|2 MeSH
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Carbon Dioxide: adverse effects
|2 MeSH
650 _ 2 |a Carbon Dioxide: administration & dosage
|2 MeSH
650 _ 2 |a Iodine: adverse effects
|2 MeSH
650 _ 2 |a Acute Kidney Injury: chemically induced
|2 MeSH
650 _ 2 |a Acute Kidney Injury: prevention & control
|2 MeSH
650 _ 2 |a Angiography: methods
|2 MeSH
650 _ 2 |a Angiography: adverse effects
|2 MeSH
700 1 _ |a Reimer, Peter
|b 1
700 1 _ |a Mahnken, Andreas H
|0 0000-0001-8077-9306
|b 2
700 1 _ |a Bellin, Marie-France
|b 3
700 1 _ |a Bertolotto, Michele
|b 4
700 1 _ |a Brismar, Torkel
|b 5
700 1 _ |a Correas, Jean-Michel
|b 6
700 1 _ |a Deike-Hofmann, Katerina
|0 P:(DE-2719)9001745
|b 7
700 1 _ |a Dekkers, Ilona A
|b 8
700 1 _ |a Geenen, Remy W F
|b 9
700 1 _ |a Heinz-Peer, Gertraud
|b 10
700 1 _ |a Mallio, Carlo A
|b 11
700 1 _ |a van der Molen, Aart J
|b 12
700 1 _ |a Quattrocchi, Carlo C
|b 13
700 1 _ |a Radbruch, Alexander
|0 P:(DE-2719)9001861
|b 14
|u dzne
700 1 _ |a Roditi, Giles
|b 15
700 1 _ |a Romanini, Laura
|b 16
700 1 _ |a Sebastià, Carmen
|b 17
700 1 _ |a Stacul, Fulvio
|b 18
700 1 _ |a Clement, Olivier
|b 19
773 _ _ |a 10.1007/s00330-025-12001-5
|g Vol. 35, no. 12, p. 7680 - 7687
|0 PERI:(DE-600)1472718-3
|n 12
|p 7680 - 7687
|t European radiology
|v 35
|y 2025
|x 0938-7994
856 4 _ |u https://pub.dzne.de/record/282472/files/DZNE-2025-01295.pdf
|y Restricted
856 4 _ |u https://pub.dzne.de/record/282472/files/DZNE-2025-01295.pdf?subformat=pdfa
|x pdfa
|y Restricted
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 7
|6 P:(DE-2719)9001745
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 14
|6 P:(DE-2719)9001861
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-353
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Clinical and Health Care Research
|x 0
914 1 _ |y 2025
915 _ _ |a DEAL Springer
|0 StatID:(DE-HGF)3002
|2 StatID
|d 2024-12-28
|w ger
915 _ _ |a DEAL Springer
|0 StatID:(DE-HGF)3002
|2 StatID
|d 2024-12-28
|w ger
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2024-12-28
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2024-12-28
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2024-12-28
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2024-12-28
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2024-12-28
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2024-12-28
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2024-12-28
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b EUR RADIOL : 2022
|d 2024-12-28
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2024-12-28
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2024-12-28
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b EUR RADIOL : 2022
|d 2024-12-28
920 1 _ |0 I:(DE-2719)5000075
|k AG Radbruch
|l Clinical Neuroimaging
|x 0
980 _ _ |a journal
980 _ _ |a EDITORS
980 _ _ |a VDBINPRINT
980 _ _ |a I:(DE-2719)5000075
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21